New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
After a conference lacking the wow factor, biotech winners and losers emerge.